Key result
Among 22,500 newly diagnosed cancer patients potentially eligible for VEGF antagonists, hypertension was the most prevalent cardiovascular comorbidity at 26.0%.
Why the study?
Cardiovascular disease prevalence is known after VEGF inhibitor use, but data regarding cardiovascular disease-related comorbidities in cancer patients before active cancer treatment are lacking.
Cross-Sectional (n=22,500)
No
Cancer patients potentially eligible for VEGF antagonists have a high baseline burden of cardiovascular comorbidities, particularly severe and poorly controlled hypertension, necessitating careful cardiovascular risk assessment before initiating antiangiogenic therapy.
High pre-treatment CVD burden in cancer patients warrants screening before VEGF inhibitors; observational data leaves open outcome impact.
BACKGROUND: Recent studies have reported the prevalence of cardiovascular diseases (CVDs) among cancer patients following the use of the vascular endothelial growth factor (VEGF) signaling inhibitors. However, data for patients with a history of cancer before active cancer treatment are lacking. This study aims to investigate the distribution of CVD-related comorbidities before cancer treatment in potential VEGF antagonists candidates. METHODS: A total of 22 500 newly diagnosed cancer patients registered from 1 January 2011 to 31 December 2017 were included. Cancer patients with colorectal cancer (CRC), renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC), and lung cancer were selected. RESULTS: Hypertension (HTN), coronary heart diseases, atrial fibrillation, and heart failure were top CVD comorbidities among studied cancers. HTN was the most prevalent CVD (26.0%). The prevalence of HTN in RCC, CRC (33.5 and 29.4% respectively) was significantly higher than that in HCC, lung cancer, and thyroid cancer patients (25.1, 24.5, and 23.1%, respectively). Among cancer patients with HTN, the majority of cancer patients fall in grade III (75.7%) and very high cardiovascular risk level (85.4%). Out of the 5847 HTN patients, 26% were not in antihypertensive use, and 34.2% failed to achieve the target blood pressure. CONCLUSION: Cancer patients carry a high burden of CVD-related comorbidities before the application of VEGF antagonists. HTN is the most prevalent comorbid condition, and cancer patients with HTN constitute substantial cardiovascular risks and a higher co-prevalence of other CVDs.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) conducted a cross-sectional in Newly diagnosed cancer (colorectal, renal cell, thyroid, hepatocellular, lung) (n=22,500). Potential eligibility for VEGF antagonists was evaluated on Prevalence of hypertension. Among 22,500 newly diagnosed cancer patients potentially eligible for VEGF antagonists, hypertension was the most prevalent cardiovascular comorbidity at 26.0%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: